Safety and Efficacy of the SurVeil™ Drug-Coated Balloon

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 446 participants.

Also called NCT03241459

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 446 participants (enrolled count) (from the registry)
Sponsor
SurModics, Inc. (from the registry)
Registry
  • NCT NCT03241459
Other papers using this trial's data
  • Editor's Choice - Results of SurVeil Versus IN.PACT Admiral Paclitaxel Coated Balloons in Femoropopliteal Arteries: 24 Month Outcomes of the Randomised TRANSCEND Study European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2025-03 DOI, PubMed 39615582

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Austria, Belgium, Czechia, Germany, Italy, Latvia, New Zealand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03241459. Randomized; single masking; primary purpose treatment. Start 2017-10-23 (actual); primary completion 2020-09-15 (actual). Results posted on 2024-04-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of the SurVeil™ Drug-Coated Balloon
Acronym
TRANSCEND
Condition
Peripheral Arterial Disease
Condition
Peripheral Vascular Disease
Condition
Artery Disease, Peripheral
Condition
Femoropopliteal Artery Occlusion
Intervention (Device)
Surmodics SurVeil DCB
Intervention (Device)
Medtronic IN.PACT Admiral DCB
Lead sponsor
SurModics, Inc. (class: industry)

Record details

Record id
cardio:ct-nct03241459
Content hash
d61e55e39a082b380fd497ccf3a2582eb12ec5dd2cda2d32cb17e82408ca45d4